Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 4, 2006, Pages 508-512

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   D'Angelo, Angela ^a   Tinelli, Carmine ^c   Ciccarelli, Leonardina ^a   Piccinni, Mario N ^a   Pricolo, Fabio ^a   Salvadeo, Sibilla ^a   Montagna, Lorenza ^a   Gravina, Alessia ^a   Ferrari, Ilaria ^a   Galli, Simona ^a   Paniga, Sonia ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Doxazosin; High sensitivity C reactive protein; Hypertension; Inflammation; Nitrite nitrate plasma levels

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; DOXAZOSIN; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; HYPOTHESIS; INFLAMMATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; NITRATES; NITRIC OXIDE; NITRITES;

EID: 33748196336     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211743.93701.eb     Document Type: Article

References (44)

1. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
2. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
3. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
4. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
5. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
6. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844.
7. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
8. Chae CU, Lee RT, Rifai N, et al. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399-403.
9. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003;21:1841-1846.
10. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
11. Pirro M, Bergeron J, Dagenais GR, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 2001;161:2474-2480.
12. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
13. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-397.
14. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
15. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
16. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
17. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
18. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
19. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
20. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the rennin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-1266.
21. Engstrom G, Janzon L, Berglund G, et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol. 2002;22:2054-2058.
22. Parissis JT, Korovesis S, Giazitzoglou E, et al. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int J Cardiol. 2002;83:13-21.
23. Ferri C, Desideri G, Baldoncini R, et al. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes. 1998;47:660-667.
24. Derhaschnig U, Shehata M, Herkner H, et al. Increased levels of transforming growth factor-beta1 in essential hypertension. Am J Hypertens. 2002;15:207-211.
25. Pockley AG, De Faire U, Kiessling R, et al. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens. 2002;20:815-820.
26. Hofman FM, Chen P, Jeyaseelan R, et al. Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. Blood. 1998;92:3064-3072.
27. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623-1629.
28. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541.
29. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol. 1998;274:F580-F586.
30. Bae JH, Bassenge E, Lim DM, et al. Effects of lacidipine on vascular responses in patients with coronary artery disease. Int J Cardiol. 2005;101:377-383.
31. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol. 2003;41:866-869.
32. Sever PS. Alpha 1-blockers in hypertension. Curr Med Res Opin. 1999;15:95-103.
33. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183.
34. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
35. 15N] nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
36. Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
37. Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
38. Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol. 2005;46:735-739.
39. Escobar E. Hypertension and coronary heart disease. J Hum Hypertens. 2002;16:S61-S63.
40. Escobales N, Crespo MJ. Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol. 2005;3:231-246.
41. Ungvari Z, Csiszar A, Huang A, et al. High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase. Circulation. 2003;108:1253-1258.
42. Ungvari Z, Csiszar A, Kaminski PM, et al. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol. 2004;165:219-226.
43. Raij L, Hayakawa H, Coffee K, et al. Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. Am J Hypertens. 1997;10:1257-1262.
44. Chait A, Gilmore M, Kawamura M. Inhibition of low density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha 1-adrenergic anti-hypertensive agent. Am J Hypertens. 1994;7:159-167.